The BH3-only protein BAD binds to Bcl-2 family proteins through its BH3 domain. Recent studies suggest that BAD binds to both Bcl-2 and Bcl-X L , however mediates its proapoptotic functions through inhibition of Bcl-X L , but not Bcl-2. In this paper we addressed this issue using a BAD mutant within the BH3 domain, by substitution of Asp 119 with Gly (BAD D119G ), which selectively abrogates an ability to interact with Bcl-2. Confocal microscopy revealed that mutation of BAD at D119 does not affect BAD targeting to the mitochondrial membrane in serum-starved COS-7 cells. However, co-precipitation assays indicated that, whereas wild-type BAD (BADwt) directly interacts with Bcl-2 and Bcl-X L , BAD D119G interacts only with Bcl-X L . Nevertheless both BADwt and BAD D119G could introduce apoptosis and diminish the anti-apoptotic effect of Bcl-2 and Bcl-X L in a similar manner in a co-transfection assay. These data thus suggest that Asp119 is a crucial site within the BH3 domain of BAD for interaction of BAD with Bcl-2, but is dispensable for the interaction of BAD with Bcl-X L , for its targeting to mitochondria, and most importantly, for its pro-apoptotic functions. Thus, we confirm that neutralization of Bcl-2 function is marginal for BAD-mediated apoptosis.
Introduction
Bcl-2 family proteins can function to either positively or negatively regulate apoptosis. Anti-apoptotic members of this family include Bcl-2, Bcl-X L , Bcl-w, BHRF1, and E1B-19K, while pro-apoptotic family members include Bax, Bak, and Bok. These molecules share homologous domains BH1 to BH4 (reviewed in 1, 2 ). Bcl-2 proteins interact with other molecules which express an a-helical structure termed the BH3-domain and this interaction is believed to be important in the regulation of apoptosis (reviewed in 3 ) . A large number of BH3-only proteins have been identified including BAD, Bid, Bik, Bim, Bmf, 4 BNIP3, Hrk, and Noxa. 5 All of these BH3-only proteins are pro-apoptotic molecules and their pro-apoptotic activity is believed to be mediated via interaction with Bcl-2 family proteins. Thus the BH3 domain of these proteins is believed to be crucial for their pro-apoptotic functions.
BH3-only proteins can be divided into two groups. The first group of BH3-only proteins, which includes BAD and Bim, can bind anti-apoptotic molecules selectively, and inactivate their anti-apoptotic functions. For example, BAD is phosphorylated by survival signals, bound to 14-3-3 scaffold proteins and localized in the cytoplasm in an inactive form. 6 ± 8 Once survival signals are abrogated BAD is dephosphorylated, dissociated from 14-3-3 and localized to the mitochondria. Free, mitochondrial BAD molecules are then believed to interact with either Bcl-2 or Bcl-X L and neutralize their anti-apoptotic functions. Similarly, Bim is normally complexed with the microtubule-associated dynein light chain LC8. However once death signals are activated Bim is released from the complex. Free Bim then binds to Bcl-2 or Bcl-X L and inactivates their anti-apoptotic functions. 9 Thus inhibition of the anti-apoptotic functions of Bcl-2 family members appears to be a pivotal role of this group of pro-apoptotic BH3-only molecules. The second group of BH3-only proteins, which is exemplified by Bid, can bind to both anti-apoptotic and pro-apoptotic Bcl-2 family members. Bid is localised in the cytoplasm in non-apoptotic cells. However activated caspase-8 cleaves p22 Bid to generate a p15 active tBid fragment which is then targeted to the mitochondria where it binds to the pro-apoptotic Bcl-2 family members Bax or Bak as well as to the anti-apoptotic Bcl-2.
10 ± 12 Formation of tBid-Bax or tBid-Bak oligomers induces apoptotic signals. Importantly, neutralization of anti-apoptotic Bcl-2 family members is believed to play only a marginal role in induction of apoptosis by these proteins.
Recently, it has been found that BAD and Bim, which belong to the first group of BH3-only proteins described above, require expression of Bax or Bak for their proapoptotic functions. 13 However since neither BAD nor Bim can directly interact with Bax or Bak it is unlikely that they can directly activate Bax or Bak. Indirect activation of Bax or Bak via inactivation of Bcl-2 or Bcl-X L has been proposed. 13 As described above the pro-apoptotic functions of BAD appear to be directly mediated through interaction of BAD with Bcl-2 or Bcl-X L via the BH3 domain of BAD and subsequent inactivation of the pro-apoptotic activity of Bcl-2 or Bcl-X L . In fact, elimination of the entire BH3 domain from BAD abrogates its ability to interact with Bcl-2 family members and simultaneously abrogates its proapoptotic activity. 8 Although BAD can interact with both Bcl-2 and Bcl-X L , BAD binds more strongly to Bcl-X L than Bcl-2 and BAD can reverse the death repressor activity of Bcl-X L , but not that of Bcl-2. 6 In addition, survival signals induce the phosphorylation of BAD, which results in its dissociation from Bcl-X L , but not from Bcl-2.
14 The accumulated data therefore suggests that the pro-apoptotic function of BAD is primarily mediated via its neutralization of Bcl-X L , and that the neutralization of Bcl-2 by BAD plays a marginal role in this function of BAD. However, these studies are all indirect observations and it is also conceivable that the death repressor activity of Bcl-2 is much stronger than that of Bcl-X L , and thus can overcome the death activity of BAD.
Since BAD interacts with both Bcl-2 and Bcl-X L via the BH3 domain, but interacts more strongly with Bcl-X L , 6 it was a possibility the BAD might interact with these two molecules via different regions of the BH3 domain. To date, at least three reports have indicated that replacement of the conserved leucine (L) residue within the BH3 domain of BAD, Noxa or Bmf with alanine (A) extensively reduced their ability to bind BCl-2 or Bcl-X L and abolished their proapoptotic activity. 4, 5, 8 However, to our knowledge, there has been no study to investigate whether a second residue, aspartic acid (D) at position 119, which is also well conserved among BH3-domains of Bcl-2 family proteins, could contribute to the binding and pro-apoptotic function of BH3-only proteins. We therefore generated a mutant form of BAD with an amino acid substitution of Gly for Asp119 within the BH3 domain (BAD D119G ) and tested the effect of this mutation on BAD protein ± protein interactions and BAD function. We found that this mutation abolished the ability of BAD to interact with Bcl-2, but had no effect on its binding to Bcl-X L . Thus different regions within the BH3 domain of BAD appear to differentially contribute to the interaction of BAD with Bcl-2 and Bcl-X L . Importantly, BAD D119G was still targeted to the mitochondria and could induce apoptosis in COS-7 cells as effectively as BADwt. In addition, they can reverse the death repressor activity of Bcl-2 and Bcl-X L in a similar level. This study is the first conclusive demonstration that BAD can induce apoptotic signals independently of its interaction with the anti-apoptotic Bcl-2.
Results

BAD overexpression augments apoptosis in COS-7 cells
The BH3-only protein BAD is abundantly expressed in many epithelial cells and functions to induce apoptotic signals. 6 ± 8,15 This suggests that BAD may play pivotal roles in the maintenance of epithelial structure by execution of excess or abnormal cells. To analyze the function of BAD in epithelial cell death, and the role of the BH3 domain of BAD in this function, we expressed GFP-tagged human full-length BAD (BADwt) or its BH3 domain deletion mutants in kidney epithelial COS-7 cells. When transfectants were deprived of FCS after transfection, overexpression of BADwt strongly induced cell death, but a BAD mutant, in which the entire BH3 domain has been deleted, could not induce cell death signals ( Figure 1A ). This indicates that BAD overexpression is able to augment apoptosis in COS-7 cells, and confirms previous observations indicating that the BH3 domain of BAD is essential for induction of apoptosis and that deletion of the BH3 domain totally abrogates pro-apoptotic functions of BAD.
7
BADD119G mutant has proapoptotic activity
The BH3 domains are well conserved among the BH3-only protein family and other Bcl-2 family members. Alignment of amino acid sequences of these BH3 domains clearly reveals two highly conserved residues, leucine (L) and aspartic acid (D) as shown in Figure 1B . Although the conserved leucine has been reported to be critical for pro-apoptotic activity of BAD there have been no studies to date on the role of the conserved aspartic acid. We therefore determined the effect of a point mutation at this conserved aspartate on the proapoptotic activity of BAD. For this purpose we generated a mutant BAD (BAD D119G ) in which the aspartate at aa 119 was mutated to glycine (G) and investigated its pro-apoptotic activity in COS-7 cells. Transfection of a BAD D119G cDNA expression vector resulted in a lower level of BAD expression compared to transfection of wild-type BAD (BADwt) ( Figure  1C ). However BAD D119G displayed a similar pro-apoptotic activity to that of BADwt, as assessed by cell death and activation of caspase-3 ( Figure 1D , E). Thus the BAD D119G mutant may even have a higher pro-apoptotic activity than BADwt. Furthermore the well-conserved Asp among Bcl-2 family members appears to be dispensable for the proapoptotic activity of BAD.
Mutation of BAD at aa119 in the BH3 domain abrogates its interaction with Bcl-2
The BH3 domain of BAD is believed to be crucial for the interaction of BAD with Bcl-2 family members and subsequent inactivation of Bcl-2 pro-apoptotic function. We therefore determined whether mutation of BAD at the conserved D119 position could alter the interaction of BAD with Bcl-2 family proteins. For this study we expressed both BADwt and BAD D119G as GST fusion proteins and determined their interaction with Bcl-2 proteins in lysates of Bcl-2-transfected HEK 293 cells. The purified GST, GST-BADwt and GST-BAD D119G proteins used for the experiment are shown in Figure 2A . The fusion proteins were immobilized on glutathione beads and incubated with a total cell lysate of HEK 293 cells transfected with full-length, GFP-labeled Bcl-2 proteins. Binding of Bcl-2 to the fusion proteins was detected following Western blotting with an anti-GFP antibody. As shown in Figure 2B only GST-BAD but not GST-BAD D119G or GST alone could specifically bind to Bcl-2. Thus mutation of BAD at D119 can abolish its ability to bind to Bcl-2. To confirm this finding we also carried out the reciprocal experiment to determine if GST-Bcl-2 proteins could co-precipitate GFPBADwt or GFP-BAD D119G proteins expressed in HEK 293 cells. The purified human full-length GST-Bcl-2 fusion protein used for this experiment is shown in Figure 2C . When GSTBcl-2, immobilized on glutathione beads, was incubated with lysates of HEK 293 cells expressing GFP-BADwt or GFP-BAD D119G only the BADwt and not the BAD D119G , was specifically co-precipitated by GST-Bcl-2 ( Figure 2D ). We thus conclude that mutation of BAD at D119 abrogates the binding of BAD to Bcl-2. Since BAD D119G can still induce apoptosis ( Figure 1 ) this data indicates that the pro-apoptotic activity of BAD is not necessarily mediated via inhibition of the anti-apoptotic function of Bcl-2.
The BAD D119G mutant is able to bind to Bcl-X L . and has similar anti-apoptotic activity in the presence of Bcl-2 or Bcl-X L Previous data, discussed above, suggests that the proapoptotic function of BAD may be mediated via its interaction with Bcl-X L rather than Bcl-2. 6 We thus determined whether mutation of BAD at D119 could also abrogate the binding of BAD to Bcl-X L . Incubation of GST-BAD fusion proteins with GFP-Bcl-X L clearly revealed that BAD D119G is able to bind to Bcl-X L ( Figure 3A) . The reciprocal experiment confirmed that BAD D119G can bind to Bcl-X L ( Figure 3B ). This suggests that the observed pro-apoptotic activity of BAD D119G (Figure 1 ) might be mediated by interaction of BAD D119G with Bcl-X L and further suggests the hypothesis that Bcl-2 may be irrelevant for the pro-apoptotic activity of BAD. As a further test of the importance of Bcl-2 for BAD pro-apoptotic activity we determined whether the pro-apoptotic functions of BADwt and the BAD D119G mutant were affected differently following co-transfection with Bcl-2 or Bcl-X L . Co-transfection of BADwt or BAD D119G with Bcl-2 or Bcl-X L resulted in similar levels of expressed proteins in COS-7 cells ( Figure 4A ). Augmentation of caspase-3 activity following serum deprivation of transfected cells for 18 h was taken as a measure of apoptotic activity. Although a previous report demonstrated that BAD can reverse the anti-apoptotic activity of Bcl-X L but not that of Bcl-2 in hematopoietic transfectants, 6 the augmented caspase-3 activity induced by BADwt or BAD D119G (see Figure 1 ) was similarly inhibited following co-transfection of either of the BAD proteins with Bcl-2 or Bcl-X L ( Figure 4B ). Thus the proapoptotic function of BAD can be diminished by both Bcl-2 and Bcl-X L . More importantly, since the anti-apoptotic activity of Bcl-2 was similar in the presence of co-transfected BADwt or the BAD D119G mutant with which it cannot interact, this observation further suggests that interaction between Bcl-2 and BAD is marginal for the pro-apoptotic function of BAD at least in COS-7 cells. The BAD D119G mutant is targeted to mitochondria
It is well established that BAD is activated and targeted to the mitochondria during the induction of the apoptotic process following exposure of cells to a variety of apoptotic stimuli or following deprivation of survival signals. 6,7,16 ± 18 We thus used GFP-tagged BADwt and BAD D119G constructs to investigate if mutation of BAD at D119 could alter its subcellular localization in COS-7 cells grown under normal or apoptosis-inducing conditions. Transfected COS-7 cells were therefore cultured in the presence (normal conditions) or absence (apoptosis-inducing conditions) of FCS. In FCSdeprived transfectants, confocal microscopical analysis revealed that both GFP-tagged BADwt and the BAD D119G mutant are visible in the cytoplasm at 12 h following genetransfection, especially at the perinuclear region. At 24 h following transfection, extensive overlap of the GFP-BAD signals with the mitochondrial MitoTracker marker dye was observed ( Figure 5 ). When transfectants were cultured in the medium in the presence of FCS, the overlap of the BAD signals with mitochondria was substantially reduced although still observable (data not shown). These results suggested both that overexpression of BAD per se can result in localization of activate BAD to the mitochondria and that the mutant BAD D119G maintains its ability to be targeted to the mitochondria both in response to apoptotic stimuli and even independently of them. (Figure 5 ). In contrast BAD deletion mutants, in which the BH3 domain has been completely removed, did not show any distinct overlap with MitoTracker regardless of the culture conditions. Thus, although the BH3 domain of BAD is required for targeting to mitochondria, mutation of D119 to G within this domain does not alter BAD mitochondrial localization. Since this mutation abrogates interaction of BAD with Bcl-2 this data also suggests that mitochondrial targeting of BAD does not require interaction with Bcl-2 and provides further support for the hypothesis that Bcl-2 interaction is not important for BAD pro-apoptotic function.
Discussion
In this paper we demonstrate that the pro-apoptotic activity of BAD is not mediated by interaction with Bcl-2 and subsequent inhibition of Bcl-2 anti-apoptotic activity. Studies carried out to date provided indirect evidence that BAD pro-apoptotic activity selectively neutralizes Bcl-X L , but not Bcl-2. 6, 8 In this study we demonstrated that BAD can neutralize both Bcl-2 and Bcl-X L at a similar level in COS-7 cells. In addition, a BAD D119G mutant that is unable to bind Bcl-2, still retains its pro-apoptotic activity and can neutralize both Bcl-2 and Bcl-X L . These data strongly suggest that previous observations showing selective inhibitory effect of BAD on Bcl-X L is not general. Indeed, a recent report shows that BAD can induce apoptosis in cells overexpressing Bcl-2 or Bcl-X L in COS-7 and leukemic cells. 19 Thus, previous data could not exclude the possibility that BAD cannot neutralize Bcl-2 because of its strong anti-apoptotic activity in some cell types. In this regard, we have conclusively shown that neutralization of Bcl-2 functions is totally dispensable for the pro-apoptotic activity of BAD.
Recently, a novel phosphorylation site, S170 has been identified as a regulator of BAD pro-apoptotic activity. Since mutation of this region (Ser170 to Ala) results in an enhanced ability of BAD to induce apoptosis, phosphorylation of BAD at S170 contributes to inactivation of its proapoptotic activity. 20 Importantly, the inactive mutant (Ser170 to Asp) can still associate with Bcl-X L , although they do not induce apoptosis. Thus, the association of BAD with Bcl-X L is not sufficient to introduce apoptosis. This implies that though retained pro-apoptotic functions of our mutant BAD D119G appears to depend upon its ability to interact with Bcl-X L , other or additional mechanism(s) may rather be involved in its pro-apoptotic activity.
As shown in this and previous papers, 8 deletion of the entire BH3 domain of BAD abrogates both mitochondrial targeting and the pro-apoptotic functions of BAD. Thus, BH3 is a crucial region for pro-apoptotic functions of BAD. The BH3 domain of BAD contains two conserved residues, an L at position 114 and a D at aa119. A previous report indicated that mutation of the L residue strongly reduces the ability of BAD to interact with Bcl-X L or Bcl-2 and destroys BAD pro-apoptotic functions. 8 In this study, we found that a single amino acid substitution of BAD at D119 within the BH3 domain selectively destroyed its ability to interact with Bcl-2, but not with Bcl-X L . In this regard, our study sheds light on the importance of the three-dimensional (3D) conformation of the BH3 domain in BAD function. To date, there have been several studies of the solution structures of Bcl-2 family members. Studies of Bid and Bcl-X L reveal that their BH3 domains contain an ahelical structure in which highly conserved hydrophobic residues (including the conserved L residue) are surface exposed and available for binding to a hydrophobic cleft in another molecule. 21 ± 23 This hydrophobic cleft is considered to be crucial for the formation of heterodimers with other Bcl-2 family members. In contrast, the side chain of the highly conserved charged residue D95 of Bid extends towards the interior of Bid yet is partially surface exposed and is thus in a position to form a salt bridge with another Bcl-2 family member. 22 The predicted structure of BAD indicates that the charged D156 residue in murine BAD (D119 in human BAD) is similarly positioned. 8 Thus, it seems likely that the D119 residue, which was mutated in this study, may contribute to the formation of a salt bridge which is crucial for heterodimerization with Bcl-2, but not with Bcl-X L .
Our data also indicate that the interaction of BAD with Bcl-2 is marginal for its recruitment to the mitochondria. Previous reports suggest that BAX can contribute to the recruitment of Bid to the mitochondria. 24, 25 However, there has been little information regarding the mechanism of mitochondrial targeting of BAD. Since neither we, nor others, 26 can detect a distinct interaction between BAX and BAD in co-precipitation assays (Figure 2) , it is unlikely that BAX can directly translocate BAD to the mitochondria. It is rather conceivable that the interaction with Bcl-X L is required for the translocation, since our mutant BAD D119G can interact only with Bcl-X L and has an ability to translocate to the mitochondria. It must be noted however that tBid expression induces a conformational change in Figure 5 Mitochondrial localization of BADwt, BAD D119G and dBAD. COS-7 cells were transfected with either pEGFP-BADwt (BAD), pEGFP-BAD D119G or pEGFP-dBAD (aa1-72) (green as indicated) and deprived of FCS for 24 h to induce apoptosis. Cellular mitochondria were then stained with MitoTracker (red) for 30 min. The cells were fixed with methanol at 7208C. Images were obtained by confocal laser microscopy. An overlay of the BAD and mitochondrial images is indicated at right (Merge) in which co-localization is indicated by a yellow color. Bars, 10 mm the amino-terminus of Bax, which allows BAK/BAX oligomerization and subsequent pore formation. 27, 28 Since the interaction between tBid and BAX is transient, it is difficult to detect their interaction and tBid is thus believed to act by a`hit-and-run' mechanism to activate BAX. Since BAD is also cleaved and activated during the apoptotic process, 29 and its pro-apoptotic functions absolutely require BAX/BAK expression, 13 we cannot exclude the possibility that BAX can transiently interact with the cleaved BAD and transport it to the mitochondria. Whatever the transport mechanism is, mutant BAD D119G can be translocated to the mitochondria as BADwt, and thus D residue within the BH3 domain is not necessary for the recruitment. Since mitochondrial targeting of BAD is obviously crucial for its apoptotic process, clarification of the precise molecular mechanism is an important avenue of future research.
Materials and methods
Cell culture and transfection
Green monkey kidney epithelial COS-7 and human embryonal HEK 293 cells were provided from the Japanese Cancer Research Resources Bank (Tokyo, Japan) and grown in Dulbecco-modified Eagles medium (D-MEM) supplemented with 10% fetal calf serum (FCS) at 378C in 5% CO 2 . The cDNA (3 mg/cm 2 ) constructs described below were transfected into these cells as indicated in the text using LipofectAMINE 2000 Reagent (GIBCO Life and Technologies, MD, USA) or Effectene (Qiagen, CA, USA).
Plasmids
Mutant BAD, in which Asp119 was replaced with Gly (BADD119G), was generated according to a PCR mutagenesis method. 30 PCR was performed with the following oligonucleotide primers: 5'-CCGGAG-GATGAGTGGCGAGT TTGTGGAC-3' and 5'-GTCCACAAACTCGC-CACTCATCCTCCGG-3' (corresponding to nucleotides 342 ± 369 in the human BAD cDNA). Full-length human BAD cDNA, (BADwt, kindly provided by Dr. JC Reed of the Burnham Institute), mutant BAD, fulllength human Bcl-2 31 and Bcl-X L 32 (kindly provided by Dr. Y Tsujimoto, Osaka University, Japan) were subcloned into GFP expression vectors pEGFPs (Clontec, CA, USA). BAD D119G , BADwt, and Bcl-2 cDNAs were also subcloned into the prokaryote pGEX 4T expression vectors (Pharmacia) for the generation of GST-fusion proteins. BAD C-terminal BH3 domain deletion mutants were generated by PCR using two different sets of oligonucleotide primers: 5'-GCGGATCCGCGGCCCCGAAAGGGGCTGGGC-3' and 5'-GCGGATCCGCCACCATGTT CCAGATCCCAGAG-3' (corresponding to amino acids 1 ± 72 in human BAD), and were subcloned into the mammalian expression plasmids pcDNA3 and pEGFP.
Reagents and antibodies
Antibody against BAD and Bcl-X L were purchased from Cell Signaling Technology (Beverly, MA, USA) and Transduction Labs (San Diego, CA, USA), respectively. Antibodies against Hsc70, BAD, Bcl-2, and GFP were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Apoptosis quanti®cation
To evaluate cell viability, cells were mixed with the same volume of 0.4% trypan blue solution, and immediately examined under the light microscope for dye exclusion. The caspase-3 colorimetric protease assay was performed following the manufacturer s protocol (CPP32/ Caspase-3 Colorimetric Protease Assay Kit, MBL). Briefly 1610 6 ± 10 7 cells were lysed in 250 ml of Cell Lysis Buffer. Total cell lysates were collected and their protein concentration was evaluated using a Protein Assay (BioRad, NY, USA). These lysates (100 mg) were mixed with the same volume of 26 Reaction Buffer, and incubated with the 4 mM DEVD-pNA caspase-3 substrate (200 mM final concentration) at 378C for 2 h. The samples were then analysed at 400 nm in a spectrophotometer.
Western blotting
As described previously, 33 following washing with ice-cold PBS, cells were lysed with 50 ml of lysis buffer containing 100 mM NaCl, 2 mM EDTA, 1 mM PMSF, 1% NP-40 and 50 mM Tris-HCl (pH 7.2). Total cell lysates were collected, separated in 15% SDS ± PAGE gels (80 mg/lane) and then electrophoretically transferred to PVDF membranes (Millipore, MA, USA) at 18 V for 70 min. Membranes were soaked into Block Ace (Dainippon Pharmacia Co., Japan) overnight at 48C and washed with washing buffer containing 140 mM NaCl, 25 mM Tris-HCl (pH 7.8) and 0.05% Tween 20. The membranes were incubated with primary antibodies overnight at 48C and thereafter incubated with the corresponding peroxidase-linked secondary antibodies (Amersham Pharmacia Biotech, IL, USA) for 1 h at room temperature. Blots were visualized by an ECL system (Amersham Pharmacia Biotech).
GST fusion protein expression and co-precipitation assays pGEX plasmids encoding full-length BADwt, BAD D119G , and Bcl-2 as GST fusion proteins were generated as described above. Expression of the fusion proteins was induced in BL21-competent bacteria with isopropyl-b-D-thiogalactoside and the fusion proteins were purified. For control experiments GST alone was generated from the pGEX-4T vector. Briefly, the bacteria were lysed with sodium deoxycholate, and the supernatant was collected and incubated with a 50% slurry of glutathione-sepharose 4B (Amersham Pharmacia Biotech). The beads were washed and resuspended in 10 mM Tris, pH 7.4, 150 mM NaCl, 5% glycerol, 1% phenylmethylsulfonyl fluoride and 1 mg/ml leupeptin. The concentration of GST-fusion-protein bound to the beads was estimated visually from Coomassie Blue-stained SDS ± PAGE with albumin standards. For co-precipitation assays whole cell lysates (1 mg) of HEK 293 transfected cells described above were incubated with 20 ml of GST-fusion-protein-bound beads for 1 ± 2 h at 48C. The beads were washed at least five times with ice-cold lysis buffer followed by separation via SDS ± PAGE. Proteins were then subjected to Western blot analysis.
Confocal laser microscopy
COS-7 cells were cultured on BSA-coated glass slides and transfected with the indicated expression vectors. Twenty-four hours following transfection, the cells were washed with cold PBS and thereafter fixed with cold methanol for 10 min. To visualize mitochondria, cells were incubated in D-MEM containing 500 nM MitoTracker RED CMXRos (Molecular Probes, OR, USA). Cells were washed three times with PBS and the coverslips were mounted on glass-slides using VECTASHILD (Vector Laboratories, Burlingame, CA, USA). Images were taken with an inverted confocal laser scanning microscopy (LSM 510; Zeiss, Jena, Germany) with a 1006 oil objective lens, and processed by Adobe Photoshop version 5.0.
